Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price
Aug 14
Have your own idea? Try our Stock Screener
U.S. Life Sciences Industry Analysis
UpdatedAug 20, 2025
DataAggregated Company Financials
Companies64
- 7D3.6%
- 3M18.6%
- 1Y-19.7%
- YTD-8.1%
Over the last 7 days, the Life Sciences industry has risen 3.6%, driven by gains from Thermo Fisher Scientific of 4.4%. In the same time, Niagen Bioscience was down 6.1%. However, the industry is down 20% over the past year. As for the next few years, earnings are expected to grow by 14% per annum.
Industry Valuation and Performance
Has the U.S. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 20 Aug 2025 | US$582.2b | US$144.2b | US$14.5b | 29.3x | 40.2x | 4x |
| Fri, 18 Jul 2025 | US$525.0b | US$142.9b | US$9.1b | 35.6x | 57.5x | 3.7x |
| Sun, 15 Jun 2025 | US$526.1b | US$142.9b | US$9.2b | 35.7x | 57.4x | 3.7x |
| Tue, 13 May 2025 | US$505.6b | US$142.7b | US$9.6b | 36x | 52.7x | 3.5x |
| Thu, 10 Apr 2025 | US$486.3b | US$142.5b | US$9.9b | 35.2x | 48.9x | 3.4x |
| Sat, 08 Mar 2025 | US$607.6b | US$143.1b | US$9.8b | 42.5x | 62.3x | 4.2x |
| Mon, 03 Feb 2025 | US$691.5b | US$143.0b | US$10.4b | 41.1x | 66.5x | 4.8x |
| Wed, 01 Jan 2025 | US$650.7b | US$142.4b | US$10.2b | 44.2x | 63.6x | 4.6x |
| Fri, 29 Nov 2024 | US$669.3b | US$142.4b | US$10.2b | 44.5x | 65.4x | 4.7x |
| Sun, 27 Oct 2024 | US$674.4b | US$142.0b | US$8.3b | 35.4x | 81.6x | 4.7x |
| Tue, 24 Sep 2024 | US$746.6b | US$141.8b | US$8.5b | 37.7x | 87.9x | 5.3x |
| Thu, 22 Aug 2024 | US$747.2b | US$141.9b | US$8.3b | 37.9x | 90.1x | 5.3x |
| Sat, 20 Jul 2024 | US$680.3b | US$141.2b | US$12.2b | 39.9x | 55.7x | 4.8x |
| Mon, 17 Jun 2024 | US$695.0b | US$141.3b | US$12.2b | 37.9x | 57.1x | 4.9x |
| Wed, 15 May 2024 | US$724.6b | US$141.5b | US$12.6b | 39.4x | 57.7x | 5.1x |
| Fri, 12 Apr 2024 | US$727.0b | US$142.0b | US$12.8b | 43x | 56.8x | 5.1x |
| Sun, 10 Mar 2024 | US$754.1b | US$142.1b | US$12.8b | 44.5x | 58.8x | 5.3x |
| Tue, 06 Feb 2024 | US$705.3b | US$141.9b | US$12.8b | 38.6x | 54.9x | 5x |
| Thu, 04 Jan 2024 | US$683.5b | US$153.8b | US$14.2b | 36x | 48.2x | 4.4x |
| Sat, 02 Dec 2023 | US$645.5b | US$153.8b | US$14.0b | 35.5x | 46.1x | 4.2x |
| Mon, 30 Oct 2023 | US$565.9b | US$153.8b | US$11.3b | 29.2x | 50.3x | 3.7x |
| Wed, 27 Sep 2023 | US$667.0b | US$154.6b | US$11.2b | 33.5x | 59.5x | 4.3x |
| Fri, 25 Aug 2023 | US$707.8b | US$154.6b | US$11.2b | 32.9x | 63.2x | 4.6x |
| Sun, 23 Jul 2023 | US$741.4b | US$155.5b | US$12.7b | 29.4x | 58.4x | 4.8x |
| Tue, 20 Jun 2023 | US$704.3b | US$152.4b | US$12.5b | 29.3x | 56.3x | 4.6x |
| Thu, 18 May 2023 | US$673.1b | US$152.4b | US$12.6b | 28.4x | 53.3x | 4.4x |
| Sat, 15 Apr 2023 | US$737.2b | US$154.6b | US$10.8b | 30.5x | 68.2x | 4.8x |
| Mon, 13 Mar 2023 | US$693.6b | US$154.5b | US$10.9b | 29.6x | 63.9x | 4.5x |
| Wed, 08 Feb 2023 | US$763.2b | US$155.6b | US$9.1b | 32x | 83.8x | 4.9x |
| Fri, 06 Jan 2023 | US$720.8b | US$155.1b | US$8.8b | 28.3x | 82.1x | 4.6x |
| Sun, 04 Dec 2022 | US$780.9b | US$155.1b | US$8.8b | 28.9x | 89x | 5x |
| Tue, 01 Nov 2022 | US$724.0b | US$154.5b | US$13.0b | 27.2x | 55.9x | 4.7x |
| Thu, 29 Sep 2022 | US$716.2b | US$152.2b | US$17.3b | 24x | 41.4x | 4.7x |
| Sat, 27 Aug 2022 | US$782.7b | US$152.3b | US$17.3b | 29.9x | 45.2x | 5.1x |
Price to Earnings Ratio
45.2x
Current Industry PE
- Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 40.2x which is lower than its 3-year average PE of 62.0x.
- The 3-year average PS ratio of 4.6x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have declined 5.8% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.82% | |
| Healthcare | 3.87% | |
| Life Sciences | 3.62% | |
| Clinical Research and Equipment | 3.62% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific | US$498.29 | 4.4% +US$7.9b | -18.9% | PE28.6x | |
| DHR Danaher | US$212.20 | 3.1% +US$4.6b | -21.9% | PE44.5x | |
| TEM Tempus AI | US$73.08 | 10.2% +US$1.2b | 24.5% | PS13.3x | |
| IQV IQVIA Holdings | US$192.35 | 3.5% +US$1.1b | -22.1% | PE26.4x | |
| ICLR ICON | US$179.64 | 6.2% +US$821.3m | -44.6% | PE17.6x |
